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Abstract A number of previous studies have revealed the
abnormal expression of various angiogenesis-related genes
or products in brain arteriovenous malformation (AVM). To
understand the molecular process of this disease, we
analyzed gene expression profiles in brain AVM. Using a
DNA microarray consisting of 17,086 genes, we identified
differentially expressed genes in 5 brain AVMs from their
draining veins, vessels retaining basic venous architecture.
Not many genes were differentially expressed between the
AVM nidus and the draining vein. When we applied an
absolute cut-off value for normalized log2 (cy5/cy3 ratio) of
0.4, 19 genes were selected. Genes such as SOX8, TRIM2,
FENA1 (ephrin A1), and AQP4 were upregulated, and
genes such as I_1000105, KRT18, IGFBP7, EMILIN-2,
and KRT14 were downregulated. Genes relating to angio-
genesis, such as vascular endothelial growth factor and
angiopoietin and other members of the ephrin family, were
not differentiated. Among differentially expressed genes
detected in this analysis, we focused on ephrin A1, a gene
related to embryogenesis and angiogenesis. The expression
of ephrin A1 was two and three to nine times higher than
that of the draining vein and normal brain, respectively,
using real-time reverse transcription-polymerase chain
reaction. For the first time, here we report the increased
expression of ephrin A1 in brain AVM, which may play an
important role in the pathogenesis of AVM.
Keywords Angiogenesis . Brain arteriovenous
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Introduction
Arteriovenous malformation (AVM) of the brain is defined
as the direct communication between one or more arteries
of the cerebral parenchyma and one or more draining veins
without the intervention of a capillary bed [3, 15, 23]. Most
brain AVM vessels are composed of large, thin-walled
dilated channels displaying fibroblast proliferation and
increased cellularity in the wall with focal deposition of
elastic tissue layers. They are generally believed to arise
when capillaries fail to develop in an area of the brain
during early embryogenesis, resulting in abnormal commu-
nications between arteries and veins. The growth of blood
vessels during embryogenesis and in adult organisms is
tightly controlled, and this growth is thought to be mediated
by soluble factors [13, 19, 27]. A number of previous
studies revealed the abnormal expression of various
angiogenesis-related genes or products in brain AVM
[7–11, 14, 16, 27].
In order to understand the molecular process of this
disease, we attempted to identify differentially expressed
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genes in brain AVMs as compared to draining veins, vessels
retaining the basic venous architecture [3, 15]. We
approached the problem by examining gene-expression
profiles. DNA microarray technology nowadays makes it
possible to simultaneously analyze the expression patterns
of thousands of genes in a given tissue [12, 18, 22]. We
here report the identification of ephrin A1, a gene involved
in embryogenesis and angiogenesis, which is overexpressed
in the nidus of brain AVM.
Materials and methods
Samples and clinical information
After institutional review and informed consent, we
obtained brain AVM specimens after resection. One
specimen of normal brain was obtained from a temporal
lobectomy that was performed for epilepsy. The brain AVM
nidus was cut into two pieces for histology and DNA
microarray analysis. The nidus was dissected from the
adjacent brain tissue in the operating theatre, and a
representative portion of nidus tissue was stored at -80°C
until analysis. Draining vein specimens were also obtained
from the five brain AVM patients. DNA microarray
analysis was performed to compare the expression levels
of genes between the nidus and draining vein of each
patient. The clinical information for patients with brain
AVM is shown in Table 1. Three patients had a history of
hemorrhage from the brain AVM. None of the patients
underwent radiosurgery. Two patients had embolization
treatment before surgical resection.
RNA preparation
Frozen sections were placed directly in Trizol reagent
(Invitrogen), homogenized for 2 min on ice, and RNA was
isolated according to the manufacturer’s protocol. RNA
was quantified based on absorbance at 260 nm. Total RNA
was assessed for quality with an Agilent Lab-on-a-Chip
2100 bioanalyzer. Possible traces of genomic DNA
contaminating the RNA preparations were removed by
DNase I (Promega) digestion.
Labeling and hybridization
The targets for DNA microarray analysis were prepared
according to the manufacturer’s instructions. Briefly,
cyanine 3- and cyanine 5-labeled complementary RNA
(cRNA) was synthesized followed by the production of
double-stranded cDNA from 50–500 ng of total RNA with
a Human 1A oligoDNA microarray kit (Agilent). After the
purification of labeled cRNA, arrays containing 17,086
genes were hybridized with the fragmented cRNA targets at
60°C for 17 h, and then washed and dried with air. We
repeated the experiments using the same sample set, but
substituting dyes.
Data analysis
Scans were performed using an Agilent DNA microarray
scanner (model G2565BA), and the expression value for
each gene was calculated by Feature Extraction software.
Data were normalized by the LOWESS normalization
method. Only the genes deemed present on all slides were
further considered. When both cyanine5 and cyanine3 dyes
produced signal intensities lower than the cut-off [2.6×
standard deviation (SD) of background], we excluded these
genes from further analysis. We excluded a sample set
when the correlation coefficient for each pair of color
swapping was positive. We calculated the mean and SD of
log2 (r1×r2, where r1 and r2 are cy5/cy3 ratios for color
swapping) for each pair of sample sets in the entire array,
and eliminated pairs of elements whose log2 (r1×r2) was
greater than the SD from the mean. We selected genes
whose absolute value for normalized log2 (cy5/cy3 ratio)
was higher than the cut-off value determined in all sample
sets examined [1, 25].
Quantitative real time RT-PCR
To evaluate the expression level of the target genes,
quantitative RT-PCR was performed using a Sequence
Detection System, model 7700 (Perkin Elmer). Quantitative
real-time RT-PCR primers were designed using Primer 3. A
sense primer and an antisense primer were synthesized
using sequences from a database search at NCBI for human
ephrin A1 and GAPDH as follows: ephrin A1 sense primer:
Table 1 Clinical features of five patients with brain arteriovenous malformation
Patient Sex Age Grade Position Bleeding Embolization
1 M 53 I Rt posterior temporal No No
2 M 29 V Lt temporal Yes Yes
3 M 35 III Lt temporal No Yes
4 F 33 III Rt posterior temporal No No
5 M 64 II Lt anterior temporal Yes No
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TGGAACAGTTCAAATCCCAAG; ephrin A1 antisense
primer: CTCATGCTCCACCAGGTACA; GAPDH sense
primer: CAGCCTCAAGATCATCAGCA; GAPDH
antisense primer: ATCCACAGTCTTCTGGGTGG. Five
serial dilutions of each total RNA sample (100, 50, 25,
12.5, and 6.25 ng total RNA) were analyzed for each target
gene. Amplification reactions (25 μl) comprised the total
RNA samples: 2× SYBR green PCR master mix, 40×
MultiScribe reverse transcriptase and RNase inhibitor mix,
and 200 nmol/l of each primer. The thermal cycling
conditions were as follows: 30 min at 48°C for reverse
transcription, 10 min at 95°C for the AmpliTaq Gold
activation, 40 cycles of 15 s at 95°C for denaturation, and
1 min at 60°C for annealing and extension. CT values
corresponded to the cycle number at which the fluorescent
emission monitored in real time reached the threshold, set at
10 SD above the mean of the baseline emission calculated
from cycles 5 to 15. The CT values decreased linearly with
increasing target quantity and could be used as a quantita-
tive measurement of the input target number. Total RNA
concentrations from each sample were normalized by the
quantity of GAPDH mRNA, and the expression levels of
the target genes were evaluated by the ratio of the number
of target mRNA to GAPDH mRNA.
Immunohistochemical study
Immunohistochemistry was performed using paraffin-em-
bedded tissue. Heat-induced epitope retrieval was per-
formed in 10 mmol/l citrate buffer. After blocking, the slides
were then incubated with a primary antibody. The slides
were incubated with a Histofine simple stain MAX-PO
(Multi) (Nichirei) for 30 min at room temperature. The
slides were washed again and incubated with detecting
reagent. The slides were counterstained with hematoxylin.
Primary antibodies were polyclonal rabbit anti-human
ephrin A1 antibody (Zymed Laboratories). The sensitivity
and specificity of primary antibodies were verified using a
positive control (prostate) and a negative control (no
primary antibody).
Results
One sample set (patient 1, Table 1) was excluded from this
study among the five sample sets because the correlation
coefficient of color swapping was positive. When we
applied an absolute cut-off value for the normalized log2
(cy5/cy3 ratio) of 0.3, 28 genes were selected; when we
applied 0.4, 19 genes were selected. Table 2 shows six
upregulated genes in the nidus of brain AVM compared to
the draining vein. Table 3 shows 13 genes downregulated in
the nidus of brain AVM compared to the draining vein. We
examined the signal-intensity ratios of housekeeping genes
and genes previously reported to be related to the
pathogenesis of brain AVM: ACTB (beta actin); GAPDH
(glyceraldehydes-3-phosphate dehydrogenase); VEGF
(vascular endothelial growth factor); FLT1 (Fms-related
tyrosine kinase 1); ANGPT1 (angiopoietin 1); ANGPT2
(angiopoietin 2); TIE (tyrosine kinase with immunoglobulin
and epidermal growth factor homology domains); ENG
(endoglin); ACVRL1 (activin receptor-like kinase-1),
MMP9 (matrix metalloproteinase 9) and HIF1A (hypoxia-
inducible factor 1 alpha subunit). There were no significant
differences in gene expression between the nidus of brain
AVM and the draining vein (minimum ratio <1, maximum
ratio >1) (Table 4). We also examined the signal-intensity
ratios of ephrin family genes: EPHA 1–9 (ephrin A 1–9
receptor); EPHB1–6 (ephrin B 1–6 receptor); EFNA 1–6
(ephrin A 1–6); EFNB 1–3 (ephrin B 1–3). Ephrin A6, A9,
B4, B5 receptors and ephrin A6 were not detected at all.
There were no significant differences in gene expression
between the nidus of brain AVM and the draining vein
(minimum ratio <1, maximum ratio >1) in other genes of
the ephrin family except for ephrin A1. Fig. 1 shows the
results of real-time RT-PCR in the draining vein, nidus, and
the specimen of normal brain (one sample). The experiment








8066 SOX8 1.820 3.710 SRY (sex-determining region Y)-box 8
3575 TRIM2 1.622 2.893 Protein with very strong similarity to neural activity-related RING finger (mouse
Trim2), member of the B-box zinc-finger family
10794 EFNA1 1.596 2.953 Ephrin-A1
16587 DKFZp761G058 1.554 2.519 Member of the protein-phosphatase 2C family
13012 AQP4 1.519 6.042 Aquaporin 4
7899 APCL 1.429 2.246 Adenomatous polyposis coli-like
We selected genes whose normalized log2 (signal-intensity ratio, AVM nidus/draining vein) was >0.4 in all cases examined (log2F 2=1, log2
1.32=0.4)
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was repeated three times in samples of patients 1, 4, and 5
(see Table 1). The gene expression of ephrin A1 in the
nidus was upregulated two and three to nine times higher
than that of the draining vein and normal brain specimen. In
an immunohistochemical study of eight brain AVMs,
expression of ephrin A1 was detected in astrocytes and
neurons of the perinidal parenchymal tissue, but not in the
surrounding reactive granulomatous tissue nor the normal
brain tissue nor in the AVM vessels (Fig. 2).
Discussion
The results of the DNA microarray analysis indicate that
not many genes are differentially expressed between the
AVM nidus and draining vein. When we applied an
absolute cut-off value for the normalized log2 (cy5/cy3
ratio) of 0.3, only 28 genes were selected; when we applied
0.4, 19 genes were selected. Genes such as SOX8, TRIM2,
FENA1 (ephrin A1), and AQP4 related to brain were
upregulated. Among the downregulated genes, several
genes were related to the extracellular matrix and keratin
such as I_1000105, KRT18, IGFBP7, EMILIN-2, and
KRT14. We focused on ephrin A1, a gene related to
embryogenesis and angiogenesis, among differentially
expressed genes detected in this analysis. We confirmed
the upregulation of ephrin A1 in the nidus compared to the
draining vein and the normal brain tissue using real-time
RT-PCR. Our immunohistochemical study showed that
ephrin A1 was highly expressed in astrocytes and neurons








3484 DACT1 0.265 0.505 Protein of unknown function, has high similarity to uncharacterized mouse Dact1
8938 I_1000105 0.172 0.582 Protein with high similarity to keratin 18 (human KRT18)
17701 KRT18 0.190 0.566 Keratin 18 (cytokeratin 18)
9754 I_931816 0.348 0.559 Protein with high similarity to adipocyte enhancer-binding protein 1 (mouse Aebp1)
10554 WBSCR5 0.442 0.638 Williams-Beuren syndrome chromosome region 5
6480 IGFBP7 0.308 0.647 Insulin-like growth factor binding protein 7
18522 EMILIN-2 0.380 0.659 Extracellular glycoprotein EMILIN-2
7701 RODH 0.419 0.651 Cis-retinol-androgen dehydrogenase 7
1597 FCGR3A 0.460 0.680 Low affinity IIIa receptor for Fc fragment of IgG, neutrophil-specific
phosphatidylinositol-linked membrane protein
4594 FLJ10261 0.161 0.702 Member of the DUF590 protein of unknown function family
11152 FSTL1 0.560 0.709 Follistatin-like 1 (follistatin-related protein)
5551 KRT14 0.179 0.726 Keratin 14
8081 I_964005 0.615 0.748 Retired, was a member of the ubiquitin carboxyl-terminal hydrolase family 2
We selected genes whose normalized log2 (signal-intensity ratio, AVM nidus/draining vein) was <-0.4 in all cases examined (log2 0.5=−1, log2
0.757=−0.4)









13349 ACTB 0.763 1.806 Beta actin
17973 GAPD 0.959 2.045 Glyceraldehyde-3-phosphate dehydrogenase
1036 VEGF 0.706 1.354 Vascular endothelial growth factor (VEGF)
4744 FLT1 0.755 1.260 Fms related tyrosine kinase 1 (vascular endothelial growth factor-vascular permeability
factor receptor)
16472 ANGPT1 0.694 1.203 Angiopoietin 1
2920 ANGPT2 0.432 2.646 Angiopoietin 2
13128 TIE 0.635 1.684 Tyrosine kinase with immunoglobulin and epidermal growth factor homology domains
17866 ENG 0.813 1.533 Endoglin
14292 ACVRL1 0.548 1.970 Activin receptor-like kinase-1
11124 MMP9 0.777 1.832 Matrix metalloproteinase 9 (gelatinase B, type IV collagenase)
1103 HIF1A 0.652 2.352 Hypoxia-inducible factor 1 alpha subunit
Ratio indicates AVM nidus/draining vein
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of the perinidal parenchymal tissue, but not in the
endothelial or smooth muscle cells of the AVM vessels.
Cells in normal brain tissue were not stained by ephrin A1
antibody.
Ephrin A1 was originally identified as a tumor necrosis
factor (TNF)-α-inducible gene in human umbilical vein
endothelial cells and is expressed in the developing
vasculature during embryogenesis [18, 22]. Ephrin A1
induces endothelial cell migration and capillary assembly in
vitro and angiogenesis in the corneal pocket assay in vivo
[4, 18]. These studies indicate that ephrin A1 is critical for
normal blood vessel development and suggest that the
molecule may also play a role in angiogenesis for patho-
logical processes in adults. The increasing size of AVMs
over time has been documented in the literature [26].
Recurrent AVMs after negative angiograms have also been
reported [13]. It is well known that new shunts between
arteries and veins grow after embolization of feeding
arteries.
We compared our DNA microarray data of angiogenesis-
related genes with previously published data. We found no
differences in these genes between the AVM nidus and
draining vein. The decreased expression of vascular
endothelial growth factor receptor (VEGFR), angiopoietin
1 (Ang1) and tyrosin kinase with immunoglobulin and
epidermal growth factor homology domains 2 (Tie2),
together with an increased expression of Ang2, matrix
metalloproteinase (MMP)-9, and tissue inhibitors of metal-
loproteinases (TIMPs) was reported [7–9]. Hashimoto et al.
confirmed a general correlation between many of the
previously published findings on abnormal angiogenesis-
related protein expression in brain AVM and gene micro-
array analysis [10]. Sure et al. recently indicated that in
AVMs treated with embolization before surgery the
expression of HIF1A and VEGF was significantly higher
Fig. 1 Gene expressions of ephrin A1 in the draining vein (V), nidus
of arteriovenous malformation (N), and normal brain tissue (B).
Quantitative real-time RT-PCR was repeated using samples from
patients 1, 4, and 5 in Table 1. Expression levels are expressed as
relative ratios in CT values for ephrin A1 to GAPDH
Fig. 2 Localization of ephrin
A1 in the nidus of brain AVM:
immunohistochemical study. A:
Ephrin A1-positive astrocytes in
perinidal parenchymal tissue
(original magnification 200); B:
ephrin A1-positive neurons in
the cortex of the perinidal region
(×200); C: no ephrin A1-posi-
tive cells in the surrounding
reactive granulomatous tissue of
perinidal parenchyma. Deposi-
tions of hemosiderin are seen
(×100); D: no ephrin A1-posi-
tive cells in AVM nidus (×100)
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than in patients who did not have previous endovascular
treatment [21]. In our data set there was no significant
difference of HIF1A and VEGF between AVM patients
with and without embolization before surgery. The differ-
ence may be due to the different tissues used for control
samples as comparisons to brain AVM. Previous studies all
used normal cortex as a control, whereas we selected the
draining vein as control, because most of the AVM nidus
consists of vessels with a dilated venule-like structure, and
the draining vein retains that basic venous architecture.
Moreover, our samples are heterogenous in clinical fea-
tures: the size of the nidus varies, two have a history of
bleeding, embolization was performed in two. Gene
expressions of the nidus and the vein may be affected.
Obviously, it would have been better and more informative
if the gene expression levels in the vessel and the brain
component of the nidus, the normal vein and the tissue of
the normal brain were compared individually.
Among the ephrin family, ephrin A1 was upregulated
only in the nidus of brain AVM as compared to the draining
vein. The ephrin A1 ligand is expressed predominantly in
tumor cells, and ephrin A2 receptors are expressed
primarily in a complementary fashion in tumor-associated
vasculature [17]. Treatment with soluble EphA2-Fc chime-
ric receptor results in decreased neovascularization in two
different tumor types in vascular window assays, and
EphA2-Fc of EphA3-Fc treatment results in decreased
tumor vascular density and impaired tumor progression in
vivo [2]. Although the pathological state of brain AVM is
completely different from tumor neovascularization, a
similar approach may elucidate the pathogenesis of brain
AVM and help in finding a new treatment for this disease.
Ephrin B2 is expressed in developing arterial endothelial
cells, whereas ephrin B4 receptor has a complementary
expression and is confined to venous endothelial cells. The
ephrin B4 receptor protein and ephrin B2 are therefore
considered to define the boundaries between arterial and
venous endothelial cells [5, 6]. It was recently reported that
endoglin and activin receptor-like kinase-1 (ACVRL1) are
necessary for the maintenance of distinct arterial-venous
vascular beds and that attenuation of the ACVRL1
signaling pathway is the precipitating event in the etiology
of hereditary hemorrhagic telangiectasia, a disease associ-
ated with AVM and characterized by the inappropriate
fusion of arterioles with venules [20, 24]. We did not detect
differences in the expressions of these genes between the
AVM nidus and draining vein.
In conclusion, we here report for the first time the
increased expression of ephrin A1 in the nidus of brain
AVM, which may play important roles in the development
and maintenance of AVM.
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Comments
R. Loch Macdonald, Toronto, Canada
The authors used DNA microarrays, quantitative PCR and
immunohistochemistry to determine if brain AVMs expressed different
genes compared to the draining vein of the AVM. Several assumptions
are inherent in the design, but the authors have done an excellent
series of experiments to document that there is increased expression of
ephrin A1 in brain AVMs. The immunohistochemistry suggests it is in
the brain tissue around the AVM rather than nidal vessels. The utility
of this kind of study is to now provide rationale for additional study of
upregulated genes because at this point, one cannot know if the
increase is a primary cause of AVM formation or pathogenesis or just
a secondary reaction to hemorrhage or the presence of the AVM.
However, that is what could be answered in detailed studies in an
animal model such as the rat carotid-jugular fistula model [1–4].
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Kiyohiro Houkin, Sapporo, Japan
This manuscript describes “Increased expression of ephrin A in
brain AVM.” It is a novel and distinguished finding that ephrin A is
expressed in neurons or glia in the perinidal parenchymal tissue. This
work is one of the continuing studies by Tokyo Women’s Medical
University group. Their studies have always been leading the study on
gene expression of vascular lesions. This basic study has a chance to
open the door to the translational research to the novel strategy for the
intractable AVM.
I guess that further study will be appreciated to figure out whether
this increased gene expression is the primary pathology or the
secondary reaction in the pathological processes. Samples of nidus
seem to contain parenchymal tissues, although those of draining veins
do not. It would be more informative to study the gene expression
profiles of only vascular components in nidus, drainer and normal
brain. The detailed analysis of receptor expression for ephrin A in the
vascular component would also be very helpful.
I hope that their continuous endeavor to reveal the gene expression
in vascular lesion will disclose the unknown mechanism of the
formation of AVM and other intracranial vascular lesions. I know that
there is a long way in front of us to reach the novel treatment for the
difficult AVM. However, without any doubt, I am confident that the
authors are leading researchers to develop this difficult task.
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